Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer

Documenti analoghi

• No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects
  di: Esther M. Hollander, et al.
  Pubblicazione: (2026)
• Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients
  di: Débora Maria Porto, et al.
  Pubblicazione: (2024)
• Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
  di: Ali Inal
  Pubblicazione: (2014)
• RBBP4: A novel diagnostic and prognostic biomarker for non‐small‐cell lung cancer correlated with autophagic cell death
  di: Yajing Zhan, et al.
  Pubblicazione: (2024)
• Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancer
  di: Guilherme Vieira de Mendonça Filho, et al.
  Pubblicazione: (2024)